Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

► Sipuleucel-T is the first approved autologous cellular immunotherapy. ► It is manufactured from antigen presenting cells obtained via leukapheresis. ► Sipuleucel-T has prolonged survival in Phase 3 studies in men with prostate cancer. ► Sipuleucel-T elicits robust antigen-specific cellular and humoral immune responses. ► Adverse events were generally mild to moderate and resolved within 2 days.